Iradimed (IRMD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$86.3M

Revenue (quarter)

$20.5M

Revenue growth (year over year)

+0.28%

Gross profit (trailing twelve months)

$65.5M

Gross margin

75.86%

Net income (trailing twelve months)

$23.1M

Net income (quarter)

$5.2M

Net income growth (year over year)

−9.63%

Net margin

26.70%

Return on equity

23.52%

EPS (trailing twelve months)

$1.81

Book value per share

$7.96

P/E (trailing twelve months)

49.88

Price to book

11.30

Debt to assets

11.50%

Payout ratio

66.76%

Dividend yield

1.41%

Company profile

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

• Is Iradimed (IRMD) profitable?

  Yes. Iradimed earned $23.1M in net income over the trailing twelve months, a net margin of 26.70%.

• How much revenue does Iradimed (IRMD) make?

  Iradimed generated $86.3M in revenue over the trailing twelve months, up 0.28% year over year.

• What is IRMD's P/E ratio?

  Iradimed trades at 49.9 times trailing twelve-month earnings, on an EPS of $1.81.

• How do I buy stock in Iradimed (IRMD)?

  IRMD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.